…
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Enovis Corporation is a medical technology company offering surgical and non-surgical solutions for musculoskeletal conditions, primarily in orthopedics and extremities. Long-term growth may be supported by aging demographics, rising procedure demand, product innovation and geographic expansion, which could underpin recurring revenue and margin improvement.
Key risks include intense device‑market competition, execution risk from integrating acquisitions and launching products, reimbursement and regulatory changes that affect procedure volumes, and supply‑chain or manufacturing disruptions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1159.42M | -822.92M | -67.13M | -2.07M | 165.39M |
| Minority interest | -0.82M | -0.68M | -0.53M | -1.53M | -4.62M |
| Net income | -1184.44M | -825.49M | -33.26M | -38.19M | 98.69M |
| Selling general administrative | 1070.15M | 1027.35M | 830.30M | 772.91M | 1329.38M |
| Gross profit | 1345.26M | 1180.76M | 990.78M | 869.38M | 1613.66M |
| Reconciled depreciation | 294.38M | 284.80M | 217.10M | 219.71M | 262.92M |
| Ebit | -1124.60M | -765.82M | -47.38M | -88.57M | 256.64M |
| Ebitda | -830.22M | -481.03M | 169.73M | 131.14M | 558.41M |
| Depreciation and amortization | 294.38M | 284.80M | 217.11M | 219.71M | 301.77M |
| Non operating income net other | - | - | - | -18.31M | -29.87M |
| Operating income | -1181.71M | -775.72M | -65.71M | -88.57M | 256.64M |
| Other operating expenses | 3429.76M | 2883.34M | 1772.91M | 1653.76M | 3570.02M |
| Interest expense | 34.82M | 57.10M | 19.75M | 24.05M | 72.59M |
| Tax provision | 22.29M | 4.49M | -13.29M | 36.12M | 66.69M |
| Net interest income | -34.82M | -57.10M | -19.75M | -24.05M | -72.59M |
| Non recurring | - | - | - | -19.48M | 27.64M |
| Income tax expense | 22.29M | 4.49M | -13.29M | 36.12M | 66.69M |
| Total revenue | 2248.05M | 2107.62M | 1707.20M | 1563.10M | 3854.30M |
| Total operating expenses | 2526.97M | 1956.47M | 1056.49M | 960.04M | 1329.38M |
| Cost of revenue | 902.79M | 926.87M | 716.42M | 693.72M | 2240.64M |
| Total other income expense net | 22.29M | -47.20M | -1.42M | 86.50M | -91.25M |
| Discontinued operations | - | - | - | 26.43M | -22.41M |
| Net income from continuing ops | -1181.71M | -827.42M | -53.84M | -38.19M | 98.69M |
| Net income applicable to common shares | - | - | - | -13.29M | 71.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 3834.74M | 4718.78M | 4509.33M | 4273.25M | 8515.34M |
| Intangible assets | 1236.71M | 1317.43M | 1127.36M | 1110.73M | 1675.46M |
| Other current assets | 143.50M | 144.13M | 100.01M | 48.16M | 90.73M |
| Total liab | 2342.84M | 2154.45M | 1088.63M | 823.45M | 3853.91M |
| Total stockholder equity | 1489.64M | 2562.26M | 3418.39M | 3448.09M | 4617.38M |
| Deferred long term liab | - | - | - | 4.50M | 5.20M |
| Other current liab | 344.71M | 279.96M | 198.23M | 206.73M | 479.63M |
| Common stock | 0.06M | 0.06M | 0.06M | 0.05M | 0.16M |
| Capital stock | 0.06M | 0.06M | 0.06M | 0.05M | 0.16M |
| Retained earnings | -1467.46M | -283.02M | 542.47M | 575.73M | 589.02M |
| Other liab | - | - | - | 166.99M | 606.32M |
| Good will | 718.30M | 1692.71M | 2060.89M | 1983.59M | 3467.30M |
| Other assets | - | - | - | 63.79M | 363.49M |
| Cash | 36.39M | 48.17M | 36.19M | 24.30M | 719.37M |
| Total current liabilities | 598.47M | 529.00M | 369.61M | 565.20M | 1023.58M |
| Current deferred revenue | 6.50M | 6.23M | 2.95M | 3.56M | 31.47M |
| Net debt | 1343.15M | 1356.13M | 500.23M | 286.24M | 1512.95M |
| Short term debt | 59.74M | 42.37M | 21.57M | 219.28M | 8.31M |
| Short long term debt | 35.00M | 20.03M | - | 219.28M | 8.31M |
| Short long term debt total | 1379.54M | 1404.30M | 536.42M | 310.54M | 2232.32M |
| Other stockholder equity | 3048.41M | 2973.12M | 2900.75M | 2925.73M | 4544.21M |
| Property plant equipment | - | - | - | 236.74M | 705.82M |
| Total current assets | 1207.06M | 1146.45M | 896.52M | 795.02M | 2303.28M |
| Net tangible assets | - | - | - | 353.77M | -525.38M |
| Net receivables | 442.79M | 407.03M | 291.48M | 267.38M | 638.70M |
| Long term debt | 1261.79M | 1309.47M | 466.16M | 40.00M | 2078.68M |
| Inventory | 584.38M | 547.12M | 468.83M | 426.64M | 776.29M |
| Accounts payable | 187.53M | 179.10M | 132.47M | 135.63M | 504.17M |
| Noncontrolling interest in consolidated entity | - | - | - | 1.72M | 44.05M |
| Accumulated other comprehensive income | -91.36M | -127.89M | -24.88M | -53.43M | -516.01M |
| Common stock total equity | - | - | - | 0.05M | 0.16M |
| Retained earnings total equity | - | - | - | 575.73M | 589.02M |
| Non currrent assets other | 71.95M | 68.38M | 90.25M | 80.29M | 363.49M |
| Non current assets total | 2627.68M | 3572.33M | 3612.82M | 3478.22M | 6212.07M |
| Capital lease obligations | 82.74M | 74.80M | 70.25M | 51.26M | 187.73M |
| Long term debt total | - | - | - | 40.00M | 2078.68M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 1.60M | -955.47M | -220.17M | -176.39M | -320.48M |
| Change to liabilities | - | - | - | -11.84M | 178.47M |
| Total cashflows from investing activities | -179.37M | -955.47M | -242.47M | -176.39M | -320.48M |
| Net borrowings | -36.92M | 859.23M | 217.19M | -1606.80M | -126.03M |
| Total cash from financing activities | -52.40M | 846.82M | 127.80M | -465.13M | 584.91M |
| Change to operating activities | - | - | - | -46.46M | 45.38M |
| Net income | -1183.62M | -824.82M | -33.26M | -11.76M | 76.28M |
| Change in cash | -11.78M | 3.33M | 20.54M | -695.08M | 618.30M |
| Begin period cash flow | 48.17M | 44.83M | 24.30M | 719.37M | 101.07M |
| End period cash flow | 36.39M | 48.17M | 44.83M | 24.30M | 719.37M |
| Total cash from operating activities | 217.29M | 113.50M | 134.99M | -55.86M | 356.10M |
| Issuance of capital stock | 1.32M | 1.87M | 4.77M | 5.81M | 745.18M |
| Depreciation | 294.38M | 284.80M | 217.10M | 219.71M | 262.92M |
| Other cashflows from investing activities | 1.60M | -4.84M | 32.57M | -70.94M | -216.24M |
| Change to inventory | -11.98M | 39.07M | -24.74M | -118.79M | -129.97M |
| Change to account receivables | -10.75M | -57.05M | -16.32M | -45.19M | -110.98M |
| Sale purchase of stock | - | -4.77M | - | 5.81M | 745.18M |
| Other cashflows from financing activities | -10.12M | -9.51M | -91.17M | 1120.22M | 957.25M |
| Change to netincome | - | - | - | 61.14M | 41.42M |
| Capital expenditures | 197.38M | 180.71M | 122.22M | 105.45M | 104.24M |
| Change receivables | - | - | - | -45.19M | -110.98M |
| Cash flows other operating | - | - | - | -149.13M | 34.18M |
| Cash and cash equivalents changes | - | - | - | -697.38M | 620.53M |
| Change in working capital | 15.46M | -13.93M | -27.27M | -220.49M | -17.10M |
| Stock based compensation | 32.92M | 29.66M | 34.06M | 38.95M | 35.35M |
| Other non cash items | 1060.37M | 647.81M | -28.24M | -88.59M | 20.84M |
| Free cash flow | 19.92M | -67.21M | 12.77M | -161.31M | 251.86M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ENOV Enovis Corp |
-1.46 5.10% |
27.16 | - | 7.14 | 0.61 | 1.01 | 1.27 | 22.42 |
| ABT Abbott Laboratories |
-0.36 0.33% |
109.56 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.14 0.14% |
101.66 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-0.84 0.26% |
325.03 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
2711 Centerville Road, Wilmington, DE, United States, 19808
302 252 9160
7802
| Name | Title | Year Born |
|---|---|---|
| Mr. Mitchell P. Rales | Co-Founder & Independent Chairman | 1957 |
| Mr. Matthew L. Trerotola | CEO & Director | 1967 |
| Mr. Brady R. Shirley | Pres, COO & Director | 1966 |
| Mr. Christopher M. Hix | Exec. VP of Fin. & CFO | 1962 |
| Mr. Daniel A. Pryor | Exec. VP of Strategy & Bus. Devel. | 1968 |
| Mr. John Kleckner | Principal Accounting Officer | 1977 |
| Mr. Michael S. Macek | VP of Fin. & Investor Relations | 1972 |
| Mr. Bradley J. Tandy | Sr. VP & Gen. Counsel | 1959 |
| Katie Sweet | VP of Corp. Communication | NA |
| Ms. Patricia A. Lang | Sr. VP & Chief HR Officer | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.